Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
Cancer Therapy: Preclinical

Heterodimeric IL15 Treatment Enhances Tumor Infiltration, Persistence, and Effector Functions of Adoptively Transferred Tumor-specific T Cells in the Absence of Lymphodepletion

Sinnie Sin Man Ng, Bethany A. Nagy, Shawn M. Jensen, Xintao Hu, Candido Alicea, Bernard A. Fox, Barbara K. Felber, Cristina Bergamaschi and George N. Pavlakis
Sinnie Sin Man Ng
Human Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, Maryland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bethany A. Nagy
Human Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, Maryland.Human Retrovirus Pathogenesis Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, Maryland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shawn M. Jensen
Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Cancer Center, Providence Portland Medical Center, Portland, Oregon.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xintao Hu
Human Retrovirus Pathogenesis Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, Maryland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Candido Alicea
Human Retrovirus Pathogenesis Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, Maryland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bernard A. Fox
Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Cancer Center, Providence Portland Medical Center, Portland, Oregon.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Barbara K. Felber
Human Retrovirus Pathogenesis Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, Maryland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cristina Bergamaschi
Human Retrovirus Pathogenesis Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, Maryland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: cristina.bergamaschi@nih.govGeorge.pavlakis@nih.gov
George N. Pavlakis
Human Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, Maryland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: cristina.bergamaschi@nih.govGeorge.pavlakis@nih.gov
DOI: 10.1158/1078-0432.CCR-16-1808 Published June 2017
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Additional Files
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    hetIL15 promotes tumor infiltration and persistence of adoptively transferred Pmel-1 and endogenous CD8+ T cells in the absence of lymphodepletion. A, ACT therapy in B16 melanoma-bearing mice. Pmel-1 cells (5 × 106) were adoptively transferred comparing three treatment protocols: (i) cell transfer without lymphodepletion (ACT, gray symbols), (ii) cell transfer in irradiated host (ACT+XRT, red symbols), and (iii) cell transfer plus IP hetIL15 administration (ACT+hetIL15, blue symbols). Mice were sacrificed at day 5, 7, and 12 for tumor and spleen analysis. B, The frequency of tumor-infiltrating Pmel-1 cells was determined by flow cytometry at the indicated time points after ACT for each treatment group. The number of Pmel-1 cells in each tumor was normalized per million of cells present in the tumor suspension. Bars represent mean ± SEM. Data of two independent experiments were combined. *, P < 0.05; **, P < 0.01. C, The proportion of Pmel-1 cells present in the tumors over time was calculated as percentage of the mean value at day 5 after ACT for each treatment group. Mean values ± SEM are shown. For each treatment group, r2 and significant deviation from zero were calculated by linear regression. Comparisons of the different treatment groups were performed using two-way ANOVA. **, P < 0.01; ns, nonsignificant. D, The frequency of tumor-infiltrating endogenous CD8+ T cells was determined by flow cytometry at the indicated time points after ACT for each treatment group. The number of endogenous CD8+ T cells in each tumor was normalized per million of cells present in the tumor suspension. Individual animal values and mean ± SEM are shown from data of two independent combined experiments. **, P < 0.01. E, Tumor sections from mice in the ACT (left), ACT+XRT (middle), and ACT+hetIL15 (right) treatment groups. TILs were identified by immunohistochemical staining using antibodies specific for CD3+ (white), CD4+ (orange), CD8+ (magenta), and CD90.1+ (green, staining Pmel-1 cells). A representative image (20× magnification) from one mouse/group is shown. F, Higher magnification of the selected region in ACT+hetIL15 group (white square) shows cells identified as T cells (CD3+, labeled ∧), CD4+ T cells (CD3+ CD4+, labeled +), endogenous CD8+ T cells (CD3+CD8+, labeled #), and Pmel-1 T cells (CD3+CD8+ CD90.1+, labeled *). G, The mean values of the Pmel-1 cell (left) and endogenous CD8+ T-cell (right) counts from 9–15 tumor images are shown. Five to six tumors in each treatment group were analyzed. InForm software was used to enumerate each cell type. *, P < 0.05; **, P < 0.01.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Tumor-resident Pmel-1 cells are preferentially targeted by hetIL15. A, Fold difference in Pmel-1 and endogenous CD8+ T-cell counts in tumors and spleens for mice in the ACT+hetIL15 (left, blue) and in the ACT+XRT (right, red) groups normalized to ACT alone. Bars represent mean fold change (±SEM) compared with the mean level of the animals in the ACT group (set as 1). Data were combined from three independent experiments (day 12 after ACT). **, P < 0.01. B, The percentage of Pmel-1 cells (defined by the expression of CD90.1) within the CD8+ T-cell population was assessed by flow cytometry in tumors (left), spleens (middle), and lungs (right) at days 5 and 12. Representative mice from the ACT+hetIL15 group are shown. C, The ratio of Pmel-1 cells to endogenous CD8+ T cells in tumor, spleen, and lung of mice receiving ACT+hetIL15 treatment was determined. Values from individual animals (combining data from day 5 and day 12 after ACT) and mean ± SEM are shown. Data were combined from two independent experiments. *, P < 0.05; **, P < 0.01. D, Mice implanted with B16 melanoma cells and MC38 colon carcinoma cells on opposite flanks underwent ACT+hetIL15 treatment. Fold increase in Pmel-1/CD8+ T-cell ratio was calculated for B16 tumor and MC38 tumor in comparison with spleen (set as 1) for each mouse. Analysis was performed at day 9 after ACT. **, P < 0.01.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    hetIL15 increases cytotoxic potential and IFNγ production of adoptively transferred Pmel-1 cells in the tumor. A, Tumor-resident Pmel-1 cells were analyzed for the expression of CD62L and KLRG1 markers. A representative animal for each treatment group is shown. B, The frequency of GzmB+ Pmel-1 cells in the tumor (% of total Pmel-1 cells) was determined by intracellular staining followed by flow cytometry. A representative animal for each treatment group is shown. C, The frequency of GzmB+ Pmel-1 cell in tumors is expressed as the percentage of total Pmel-1 cells (left) and number of GzmB+ Pmel-1 cells normalized per million of cells present in the tumor suspension (right); mean values ±SEM are shown for the three groups. Data collected from day 7 and day 12 after ACT were combined. *, P < 0.05; **, P < 0.01. D, The frequency of IFNγ−producing Pmel-1 cells (left) and endogenous CD8+ T cells (middle) in tumor and of Pmel-1 cells in inguinal lymph nodes (right) was determined upon 6 hours (tumor) or 12 hours (lymph node) ex vivo cultures in medium only or in the presence of the hgp10025–33 peptide. Analysis was performed at day 7 after ACT. ACT: n = 3; ACT+XRT: n = 5; and ACT+hetIL15: n = 5. *, P < 0.05; **, P < 0.01.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    hetIL15 treatment sustains tumor-resident PD-1lowGzmB+Ki-67+ Pmel-1 cells and increases tumor Pmel-1/Treg ratio. A, Percentage of Pmel-1 cells in tumor expressing the proliferation marker Ki-67 for the mice in each of the three treatment groups at day 12 after ACT. Bars represent mean ± SEM. Data from two independent experiments were combined. **, P < 0.01. B, Pmel-1 cells infiltrating the tumor were analyzed for the expression of PD-1, Ki-67, and GzmB by flow cytometry. The GzmB+ Pmel-1 cells (red dots) were overlaid on the total Pmel-1 cell population (black contour). Representative animals from the ACT (left), ACT+XRT (middle), and ACT+hetIL15 (right) treatment groups at day 12 after ACT are shown. C, The percentage of proliferating and cytotoxic Pmel-1 cells characterized by low expression of PD-1 (PD-1lowGzmB+Ki-67+) was determined in tumors at day 12 after ACT (left). The percentage of Pmel-1 cells with a phenotype consistent with exhaustion (PD-1highGzmB−Ki-67−) was also determined in the tumor at day 12 after ACT (right). The values from individual animal and mean ± SEM are shown. **, P < 0.01. D, The frequency of tumor-infiltrating Treg cells was determined by flow cytometry at day 12 after ACT for each treatment group. The number of Treg cells in each tumor was normalized per million of cells present in the tumor suspension. Bars represent mean ± SEM (left). The Pmel-1/Treg ratio was determined in tumor at day 12 after ACT for each treatment group. Bars represent mean ± SEM. **, P < 0.01 (right).

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    hetIL15 and ACT promote tumor control in the absence of lymphodepletion. Mice were implanted with 5 × 105 B16 cells SC at day −5. Mice were randomized in different treatment groups: PBS administration (black, n = 10), ACT alone (gray, n = 7), hetIL15 alone (green, n = 7), and ACT+hetIL15 (blue, n = 8) for A, and ACT alone (gray, n = 5), XRT alone (black, n = 7), ACT+XRT (red, n = 9), and ACT+hetIL15 (blue, n = 10) for B. Splenic-derived Pmel-1 cells (1 × 106/mouse) were administered at day 0. Injections of hetIL15 were performed 3 times per week for a total of 8 doses (3 μg/dose/mouse). Tumor measurements were performed every 2 to 3 days. Mean ± SEM for each time point are shown. One of three similar experiments is shown. Statistical significance was calculated using repeated measures one-way ANOVA. The P values were corrected for multiple comparisons using Holm–Sidak test (*, P < 0.05; **, P < 0.01).

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6.

    IL2 coadministration with ACT results in tumor accumulation and proliferation of Pmel-1 cells similar to hetIL15, but significantly increases the frequency of tumor-associated Tregs (A). Pmel-1 cells (5 × 106) were adoptively transferred comparing 3 treatment protocols: cell transfer without lymphodepletion (ACT, gray symbols), cell transfer plus IP hetIL15 administration (ACT+hetIL15, blue symbols), and cell transfer plus IP IL2 administration (9 μg/dose, green symbols). Mice were sacrificed at day 10 for tumor analysis. The frequency of tumor-infiltrating Pmel-1 cells was determined by flow cytometry for each treatment group. The number of Pmel-1 cells in each tumor was normalized per million of cells present in the tumor suspension. Bars represent mean ± SEM. B, Percentage of Pmel-1 cells in tumor expressing the proliferation marker Ki-67 for the mice in each of the three treatment groups at day 10 after ACT. Bars represent mean ± SEM.C, The frequency of tumor-infiltrating Tregs was determined by flow cytometry at day 10 after ACT for each treatment group. The number of Tregs in each tumor was normalized per million of cells present in the tumor suspension. Bars represent mean ± SEM (left). D, The Pmel-1/Treg ratio was determined in tumor for each treatment group at day 10 after ACT. Bars represent mean ± SEM. E, Mice were implanted with 5 × 105 B16 cells subcutaneously at day −5. Three treatment groups were compared: no treatment (gray, n = 10), ACT+hetIL15 (blue, n = 10), and ACT+IL2 (green, n = 10). Splenic-derived Pmel-1 cells (1 × 106/mouse) were administered at day 0. Intraperitoneal injections of hetIL15 and IL2 were performed 3 times per week for a total of 8 doses (3 μg/dose/mouse). Tumor measurements were performed every 2 to 3 days. Mean ± SEM for each time point is shown. *, P < 0.05; **, P < 0.01.

Additional Files

  • Figures
  • Supplementary Data

    • Supplementary Figures 1-5, Supplementary Table 1 - Supplementary Figure 1. IL-15 availability promotes proliferation and maintenance of transferred CD8+ T in the spleen of recipient mice; Supplementary Figure 2. Gating strategy for the identification of adoptively transferred Pmel-1 cells and endogenous CD8+ T cells infiltrating the tumor; Supplementary Figure 3. Absolute counts of splenic Pmel-1 and CD8+ T cells are profoundly affected by hetIL-15 treatment; Supplementary Figure 4. Evaluation of PD-1, Ki67 and GzmB expression by tumorinfiltrating Pmel-1 cells; Supplementary Figure 5. Evaluation of PD-1, Ki67 and GzmB expression by tumorinfiltrating CD8+ T cells; Supplementary Table 1. Hematological parameters during ACT treatments.
PreviousNext
Back to top
Clinical Cancer Research: 23 (11)
June 2017
Volume 23, Issue 11
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Clinical Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Heterodimeric IL15 Treatment Enhances Tumor Infiltration, Persistence, and Effector Functions of Adoptively Transferred Tumor-specific T Cells in the Absence of Lymphodepletion
(Your Name) has forwarded a page to you from Clinical Cancer Research
(Your Name) thought you would be interested in this article in Clinical Cancer Research.
Citation Tools
Heterodimeric IL15 Treatment Enhances Tumor Infiltration, Persistence, and Effector Functions of Adoptively Transferred Tumor-specific T Cells in the Absence of Lymphodepletion
Sinnie Sin Man Ng, Bethany A. Nagy, Shawn M. Jensen, Xintao Hu, Candido Alicea, Bernard A. Fox, Barbara K. Felber, Cristina Bergamaschi and George N. Pavlakis
Clin Cancer Res June 1 2017 (23) (11) 2817-2830; DOI: 10.1158/1078-0432.CCR-16-1808

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Heterodimeric IL15 Treatment Enhances Tumor Infiltration, Persistence, and Effector Functions of Adoptively Transferred Tumor-specific T Cells in the Absence of Lymphodepletion
Sinnie Sin Man Ng, Bethany A. Nagy, Shawn M. Jensen, Xintao Hu, Candido Alicea, Bernard A. Fox, Barbara K. Felber, Cristina Bergamaschi and George N. Pavlakis
Clin Cancer Res June 1 2017 (23) (11) 2817-2830; DOI: 10.1158/1078-0432.CCR-16-1808
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Grant Support
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Enhanced Delivery of SN38-TOA NPs in NBs
  • Radiotherapy with IDO1/PD-1 Blockade Treats Advanced GBM
  • TCRs against MCV T-antigens
Show more Cancer Therapy: Preclinical
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • CCR Focus Archive
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Clinical Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Clinical Cancer Research
eISSN: 1557-3265
ISSN: 1078-0432

Advertisement